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Abstract
Purpose Cardiac amyloidosis is a rare disorder, but it may
lead to potentially life-threatening restrictive cardiomyopathy.
Cardiac manifestations frequently occur in primary amyloid-
osis (AL) and familial amyloidosis (ATTR), but are uncom-
mon in secondary amyloidosis (AA). Echocardiography is the
method of choice for assessing cardiac amyloidosis. Amyloid
deposits impair the function of sympathetic nerve endings.
Disturbance of myocardial sympathetic innervations may play
an important role in the remodelling process. 123I-MIBG can
detect these innervation changes.
Methods Patients with biopsy-proven amyloidosis under-
went general work-up, echocardiography and 123I-MIBG
scintigraphy. Left ventricular internal dimensions and wall
thickness were measured, and highly refractile cardiac ech-
oes (sparkling) were analysed. Early (15 min) and late (4 h)
heart-to-mediastinum ratio (HMR) and wash-out rate were
determined after administration of MIBG.
Results Included in the study were 61 patients (30 women and
31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR).
Echocardiographic parameters were not significantly different
between the groups. Sparkling was present in 72 % of ATTR
patients, in 54 % of AL patients and in 45 % of AA patients.
Mean late HMR in all patients was 2.3±0.75, and the mean
wash-out rate was 8.6±14 % (the latter not significantly
different between the patient groups). Late HMR was signif-
icantly lower in patients with echocardiographic signs of
amyloidosis than in patients without (2.0±0.70 versus 2.8±
0.58, p<0.001). Wash-out rates were significantly higher in
these patients (−3.3±9.9 % vs. 17±10 %, p<0.001). In ATTR
patients without echocardiographic signs of amyloidosis,
HMR was lower than in patients with the other types (2.0±
0.59 vs. 2.9±0.50, p00.007).
Conclusion MIBG HMR is lower and wash-out rate is
higher in patients with echocardiographic signs of amyloid-
osis. Also, 123I-MIBG scintigraphy can detect cardiac de-
nervation in ATTR patients before signs of amyloidosis are
evident on echocardiography.
Keywords MIBG . Cardiac . Amyloidosis .
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Introduction
Amyloidosis comprises a group of diseases characterized by
deposition of protein fibrils with a cross-β-pleated sheet
molecular structure. The deposition of these amyloid fibrils
results in loss of organ function. Even though cardiac amy-
loidosis seems to be rare, in the majority of patients, amy-
loidosis can be complicated by cardiac involvement. About
50 % of all amyloidosis patients experience some cardiac
manifestations related to the disease [1]. It is frequent in
primary amyloidosis (immunoglobulin light chain, or AL
type) and familial amyloidosis (transthyretin, or ATTR type,
which leads to familial amyloidotic polyneuropathy, FAP),
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but uncommon in secondary amyloidosis (serum amyloid A
protein, or AA type). Up to 90 % of all patients with AL
amyloidosis have cardiac manifestations, but only 5 % have
clinically isolated cardiac disease. In ATTR amyloidosis,
cardiac involvement leads less frequently to systolic dys-
function and heart failure. Furthermore, symptoms are
milder and progression is slower, when compared to AL
amyloidosis.
Cardiac involvement eventually leads to a type of cardio-
myopathy in which ventricular filling is restricted, resulting
in symptoms and signs of heart failure. Heart failure occurs
in at least 25 % of all patients [1]. The presence of heart
failure is associated with a median survival of only 6 months
[1]. Amyloidosis is the most common cause of this co-called
‘restrictive cardiomyopathy’. Transthoracic echocardiogra-
phy plays an important role in the evaluation of cardiac
manifestations of amyloidosis. Nowadays it is the modality
of choice for the evaluation of amyloid deposition in the
heart [2]. The most common findings are left ventricular
(LV) wall thickening due to amyloid deposition in the myo-
cardium and highly refractile cardiac echoes (sparkling).
This is often associated with right ventricular wall thicken-
ing, diffuse valvular infiltration, dilated atria and pericardial
effusion [3]. However, with this technique, the diagnosis of
cardiac amyloidosis is often established when the disease
has already reached a relatively advanced stage, where
irreversible functional and structural myocardial changes
have occurred (remodelling). Disturbance of myocardial
sympathetic innervation may play an important role in this
remodelling process, and may even lead to sudden death due
to fatal arrhythmia [2]. Amyloid deposits impair the func-
tion of myocardial sympathetic nerve endings.
Scintigraphic imaging using 123I-MIBG is a validated
method to evaluate sympathetic innervation in the heart,
and has also been used in patients with amyloidosis
[4–6]. 123I-MIBG, derived by chemical modification of
the false neurotransmitter analogue guanethidine, and
therefore an analogue of norepinephrine (NE), enters
the sympathetic nerve terminals through a specific “up-
take-1 mechanism”. Unlike NE, 123I-MIBG is stored in
granules in the nerve terminals and is not catabolized.
In various case studies and trials, defects on 123I-MIBG
scans have been found to represent impaired cardiac
sympathetic nerve endings due to amyloid deposition
[4–9]. So, 123I-MIBG indirectly visualizes the effect of
amyloid deposition in the myocardium [10]. This tech-
nique might be able to detect early cardiac denervation
before actual heart failure occurs, and is also thought to
visualize impaired sympathetic innervation before abnor-
malities appear on echocardiography.
The purpose of this study was to determine if 123I-MIBG
scintigraphy is able to identify cardiac sympathetic denerva-
tion in patients with different types of early stage amyloidosis.
Materials and methods
Patients
A total of 63 consecutive patients (31 women, 32 men) with
systemic amyloidosis underwent 123I-MIBG scintigraphy
between June 2007 and August 2011. Diagnosis of amy-
loidosis was based on detection of amyloid in a biopsy site
typically involved in systemic amyloidosis, such as abdom-
inal fat tissue, kidney or nerve. One patient was excluded
because of insufficient histological proof of amyloid in the
biopsy. History and physical examination were used to
determine the presence of polyneuropathy. All patients un-
derwent the usual tests including 12-lead electrocardiogra-
phy (ECG), dynamic electrocardiography (Holter
investigation), radionuclide multiple gated acquisition
(MUGA) for LV ejection fraction (LVEF), 123I-labelled se-
rum amyloid P scintigraphy to evaluate total body amyloid
deposition, autonomic function testing using bedside
manoeuvres, heart rate variability analysis and echocardio-
graphic examination before 123I-MIBG scintigraphy.
For 123I-MIBG imaging, nine age-matched consecutive
normal volunteers were scanned to form a healthy control
database. All subjects were in good health and were not
taking medication, especially tricyclic antidepressants or
other sympathicomimetics that can interfere with 123I-MIBG
uptake.
123I-MIBG scintigraphy
Scintigraphy was performed after blockade of thyroid up-
take of free 123I by iodine potassium iodide (Lugol’s solu-
tion). After a 15-min rest period, subjects were injected with
185 MBq 123I-MIBG (AdreView; GE Healthcare Medical
Diagnostics, Eindhoven, The Netherlands) through an intra-
venous catheter. At 15 min (early image) and 4 h (delayed
image) after tracer administration, 10-min static anterior
view images of the chest were acquired using a Symbia S
gamma camera (Siemens Medical Systems, Knoxville, TN)
with a medium energy low-penetration parallel-hole colli-
mator, as recommended in the proposal for standardization
of 123I-MIBG scintigraphy for cardiac sympathetic innerva-
tion imaging [11]. A 15 % energy window centred on
159 keV, a 256×256 matrix size and a 1.45 zoom factor
was used.
Multiple gated equilibrium radionuclide angiography
MUGAs were standardized and performed in the left ante-
rior oblique projection after in vivo labelling of red blood
cells with 750 MBq of 99mTc-pertechnetate to determine
LVEF. Images were collected in a 64×64 matrix in 20
frames/cycle during a 10-min acquisition. The Symbia S
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gamma camera with a low-energy all-purpose collimator
was used. The camera head was positioned in the best septal
left anterior oblique projection, typically with a caudal tilt of
5–10°. R-wave triggering was performed in a 20 % beat
acceptance window with two-thirds forward and one-third
backward framing per cardiac cycle, for 20 frames per R-R
interval for a total of 6 min. Data were acquired using 64×
64 matrices in a 15 % energy window centred on the
140 keV photopeak. Processing was performed on dedicated
computers (Syngo MI; Siemens Medical Systems). For each
of the 20 frames a region of interest (ROI) was automatical-
ly drawn around the LV using a validated, fully automated,
operator-independent, contour detection algorithm. Frames
were automatically corrected for background activity. Back-
ground activity ROIs were generated automatically. All
LVEF values were generated without decimals and are high-
ly reproducible [12].
123I-MIBG scintigraphy image analysis
For planar images, LV activity was measured over the raw
static image using a ROI along the contour of the LV. A
second ROI was placed over the upper mediastinal area. The
heart-to-mediastinum activity ratio (HMR) was measured
three times, and the measurements averaged. The cardiac
123I-MIBG wash-out rate was defined as the percentage
change in activity ratio from the early to the late images
within the LV ROI as follows: [(HMRearly−HMRlate)/
HMRearly]×100 %, data being corrected for the physical
decay of 123I. Data were also compared with our local
normal database.
Heart rate variability analysis
Heart rate variability based on the 24-h Holter electrocar-
diogram was analysed during hospitalization. The following
nonspectral indices (time domain) were computed and
expressed in milliseconds: the average NN interval of nor-
mal cycles; its standard deviation (SDNN), which reflects all
the cyclic components responsible for variability; and the
SDNN index, which is the mean of all 5-min standard
deviations of NN intervals during a 24-h period.
Echocardiographic examination
The following variables were measured according to stan-
dard recommendations in the M-mode echocardiographic
examination: LV internal end-diastolic and end-systolic
dimensions, interventricular wall thickness and LV posterior
wall thickness at end-diastole. In the two-dimensional echo-
cardiographic examination, highly refractile cardiac echoes,
the so-called granular sparkling appearance, were sought.
Using Doppler recordings of transmitral flow velocity, the
ratio of peak flow velocity of LV rapid diastolic filling (peak
E) to peak flow velocity during atrial contraction (peak A)
was measured, and a ratio lower than 1 was considered
abnormal. A visually estimated LVEF of >55 % was con-
sidered normal, between 55 % and 40 % mildly disturbed,
between 30 % and 40 % moderately disturbed, and <30 %
severely impaired systolic function.
Statistical analysis
The results are expressed as means ± standard deviation, or
median (range) if the data were not normally distributed.
The differences between patient categories were evaluated




The baseline characteristics of the patients (31 women and
32 men) are summarized in Table 1. Their mean age was 62
±8.8 years. The mean age of the 9 healthy controls (6
women and 3 men) was not significantly different (52±
17 years). Of all 63 patients, 39 were diagnosed with AL
amyloidosis, 11 with AA type and 11 with ATTR type. In
one patient, the type of amyloidosis remained unclear, de-
spite extensive testing. One patient was excluded because
the presence of amyloidosis could not be confirmed histo-
logically. There was no difference in medication use be-
tween the different patient groups. Polyneuropathy was
present in 19 patients (10 AL, 1 AA and 8 ATTR). Clinical
evidence of autonomic dysfunction was present in 25
patients (18 AL, 2 AA and 5 ATTR). The clinical signs of
heart failure are also presented in Table 1. No significant
difference between the different patients groups was found
regarding these parameters. ECG abnormalities at baseline
included left axis deviation, signs of LV hypertrophy, con-
duction delay (QRS >110 ms), and microvoltage in standard
leads. Atrioventricular block recorded on Holter registration
was infrequent (ten patients): five first-degree and 1 s-
degree in AL patients and five in ATTR patients. The QRS
complex was significantly longer in ATTR patients: 104 ms
versus 88 ms in AA patients as well as AL patients (p<
0.005), but still within the normal range (<110 ms). Ventric-
ular tachycardia (VT) occurred significantly more often in
ATTR patients (median 1, range 0–13). However, the num-
ber of VTs over five beats was the same in AL and ATTR
patients (5). Median LVEF on MUGAwas 60 % (range 29–
70 %), and did not differ between the groups. The presence
of wall motion abnormalities on MUGA was not different
between the groups.
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123I-MIBG scintigraphy
123I-MIBG scans were performed within 186 days (0-
412 days) after the date that the presence of amyloidosis
was confirmed by histology. Table 2 summarizes the results
of the 123I-MIBG scans in the different patient groups and
the healthy controls. In all patients the HMR was signifi-
cantly lower than in healthy controls (mean HMR 2.3±0.75
vs. 2.9±0.58, p<0.005; Fig. 1) Furthermore, the wash-out
rate in all patients was significantly higher than in healthy
controls (mean wash-out rate 8.6±14 % vs. −2.1±10 %, p<
0.05; Fig. 2). Among all patients, the mean HMR did not
differ significantly between those with and without poly-
neuropathy or autonomic neuropathy. The wash-out rates in
patients with polyneuropathy were significantly higher (14±
10.7 vs. 6.6±15, p<0.05)), but not in patients with auto-
nomic neuropathy. The HMR was significantly lower in
ATTR patients (1.7±0.52) than in the other groups (2.5±
Table 1 Patient characteristics
at baseline Characteristic AL patients AA patients ATTR patients
Gender (n)
Male 21 3 7
Female 18 8 4
Age (years, mean ± SD) 62±8.8 64±13 56±13
Heart biopsy (n) 0 0 2
Polyneuropathy (n) 10 1 8
Autonomic neuropathy (n) 18 2 5
Signs of heart failure (n)
Cor-thorax ratio >50 (n) 6 1 4
ECG abnormalities (n) 12 3 7
NYHA class for heart failure (n)
I 22 8 8
II 17 3 3
III 0 0 0
IV 0 0 0
Hypertension(n) 27 7 5
Oedema (n) 15 3 3
Known coronary artery disease (n) 4 0 0
Medication at baseline (n)
Beta-blocker 7 3 3
ACE inhibitor 8 3 1
Antiepileptic agents 4 1 1
Selective serotonin reuptake inhibitors 2 1 1
Angiotensin-2 antagonists 3 2 2
Alpha-1 blocker 0 1 0
Laboratory values at presentation, median (range)
NT-proBNP (ng/l) 926 (38–59,544) 792 (29–38,308) 777 (80–2,596)
Troponin T (μg/l) <0.05 (<0.05-1.32) 0.01 (<0.05–0.08) <0.05 (<0.05–4.0)
MUGA parameters, median (range)
LVEF (%) 60 (32–70) 65 (51–67) 56 (29–65)
Wall motion abnormalities LV (n)
None 34 8 5
Diffuse 3 1 1
Regional 2 0 3
RVEF (n)
Normal 35 9 8
Mildly disturbed 3 0 0
Moderately disturbed 0 0 1
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0.75 in AL patients and 2.4±0.75 in AA patients, p<0.05).
In ATTR patients the HMR was significantly lower than in
healthy controls (p<0.001), but not different from that in
AL or AA patients.
The wash-out rate in healthy controls was significantly
lower than in the patients overall. It was also significantly
lower than in the ATTR patients (p<0.001) and in the AL
patients (p<0.005). There was no difference in wash-out
rate between the three patients groups. Using a wash-out
rate ≥0 %, the rate in ATTR patients was significantly higher
than in patients with other types of amyloidosis (p<0.05).
Using this cut-off, the wash-out rate in healthy controls was
significantly lower than in the patients overall (2.6±3.8 %
vs. 11±11 %, p<0.001). A wash-out rate higher than 20 %
occurred significantly more often in AL patients and ATTR
patients (p<0.05) than in AA patients.
Patients with signs of heart failure, specifically a cor-
thorax ratio >50, showed significantly lower HMR (1.78±
0.54 vs. 2.46±0.74, p00.003) and higher wash-out rates (23
±6.8 % vs. 5.8 ±13 %, p<0.001) than those without an
enlarged heart on conventional chest radiographs. Also
patients with ECG abnormalities at baseline showed lower
HMR (1.91±0.60 vs. 2.55±0.74, p00.001) and higher
wash-out rates (15±12 % vs. 5.1±14 %, p00.004) than
those with a normal ECG.
Cardiac denervation–heart rate variability relationship
There was no difference in SDNN among the three patient
groups, nor in the SDNN index.
Echocardiography
Echocardiography and 123I-MIBG scans were performed
within 81±141 days consecutively. Table 3 summarizes
the echocardiographic examination results. Left and right
ventricular wall thickness was overall normal in the different
groups, except for a slightly thicker posterior LV wall in the
ATTR patients. LV diastolic function was mildly disturbed
more frequently in AL patients. However, there were no
significant differences in the frequency of diastolic dysfunc-
tion among the different groups. The HMR and wash-out
rate were also not different between patients with and with-
out diastolic dysfunction on echocardiography. The visually
estimated LVEF was mostly normal in all three patient
groups. LVEF measured by MUGA corresponded well with
visually estimated LVEF. The combination of LVEF <40 %
and the presence of parameters of amyloidosis on echocar-
diography occurred significantly more often in the ATTR
patients (36 %).
Table 2 123I-MIBG findings
Healthy controls AL patients AA patients ATTR patients
Late HMR, mean ± SD or median (range) 2.9±0.58 2.5±0.75 2.4±0.75 1.7 (1.0–2.6)
Wash-out rate (%, mean ± SD) −2.1±10 7.0±14 5.9±14 18±8.3
Wash-out rate cut-off at 0 (%, mean ± SD) 2.6±3.8 9.6±11 8.9±11 18±8.5
Wash-out rate >20 % (n) 0 7 2 6
Fig. 1 Late HMR for all patient groups and the healthy controls
Fig. 2 123I-MIBG wash-out rates for all patient groups and the healthy
controls
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Characteristic sparkling on echocardiography appeared in
73 % of the ATTR patients, and in 54 % and 45 % in the AL
and AA patients, respectively. Of the AL patients, three had
the combination of LVEF <40 % and echocardiographic
parameters of amyloidosis. This combination occurred sig-
nificantly more often (p<0.05) in the ATTR patients (4 out
of 11).
Late HMR was significantly different between
patients with and without echocardiographic parameters
for amyloidosis, defined as sparkling and LV wall thick-
ness >11 mm (2.0±0.70 vs. 2.8±0.58, p<0.001; Fig. 3).
Also, the wash-out rate was significantly higher in these
patients (−3.3±9.9 % vs. 17±10 %, p<0.001; Fig. 4).
There was no difference in HMR or wash-out rate
among the three patient groups in patients with echo-
cardiographic parameters of amyloidosis. However, in
ATTR patients without echocardiographic parameters
of amyloidosis, HMR was lower than in patients with
the other types (2.0±0.59 vs. 2.9±0.50, p00.007).
Furthermore, wash-out rates were higher in these
patients (11±1.4 % vs. −4.6±9.3 %, p00.03). There
was also no difference in polyneuropathy or autonomic




aSparkling and LV wall thick-
ness >11 mm.
bAmyloid + LVEF <40 %.
AL patients AA patients ATTR patients
Wall thickness (mm), median (range)
Septal wall 12 (7–23) 12 (8–18) 13 (7–20)
Posterior wall 11 (8–19) 11 (9–15) 16 (8–20)
Right ventricle wall 5 (3–10) 6 (4–8) 6 (4–9)
Diastolic function (n)
Inaccessible 3 2 0
Normal 5 4 2
Mildly disturbed 22 5 3
Moderately disturbed 5 1 3
Severely disturbed 4 1 1
Amyloid parameters on echocardiograma (n) 21 5 8
LVEF on echocardiogram (n)
Normal 25 8 6
Mildly disturbed 11 3 3
Moderately disturbed 3 0 1
Severely disturbed 0 0 1
Cardiomyopathyb (n) 3 0 4
Fig. 3 Late HMR in patients with and without echocardiographic
signs of amyloidosis
Fig. 4 123I-MIBG wash-out rates in patients with and without echo-
cardiographic parameters for amyloidosis
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Discussion
Our results indicate that 123I-MIBG scintigraphy can be
used to determine cardiac sympathetic denervation in
patients with early stage amyloidosis. Furthermore, in
ATTR patients cardiac denervation can be found even be-
fore echocardiographic parameters are present. To our
knowledge, this is the first study to find a significant differ-
ence between subgroups of amyloidosis patients in echocar-
diographic findings of cardiac amyloidosis, and HMR and
wash-out rates determined by 123I-MIBG scintigraphy prior
to an intervention. Sympathetic denervation, determined by
diminished late 123I-MIBG uptake in HMR and elevated
wash-out rate, was prominent in patients with echocardio-
graphic parameters for amyloidosis. Furthermore, HMR was
lower and wash-out rates higher in patients with amyloid-
osis than in healthy controls.
In previous studies involving 123I-MIBG in patients with
amyloidosis, echocardiography was also performed. The
slight increase in wall thickness in ATTR patients and in
those with FAP is in accordance with the findings of previ-
ous studies [6–8]. In AL patients thickened ventricular walls
have been found, but only in a minority [5]. However, in
patients with FAP who had undergone liver transplantation,
an inverse correlation has been found between septal and
posterior wall thickness determined by echocardiography
and cardiac 123I-MIBG uptake after liver transplantation
[8]. These authors did not find a correlation before liver
transplantation or between echocardiographic changes and
changes in 123I-MIBG uptake after the intervention.
About 50 % of all amyloidosis patients experience cardi-
ac manifestations related to the disease, most frequently in
those with AL or ATTR. Symptoms and consequences of
cardiac amyloid deposition in AL amyloidosis are often
more frequent and severe than in FAP (causing more fatal
dysfunction). Myocardial defects in 123I-MIBG activity cor-
relate with impaired cardiac sympathetic function due to
amyloid deposition. This can be identified early in the
disease. Several studies have shown the value of HMR
and wash-out rate as indicators of sympathetic innervation
abnormalities in cardiac amyloidosis. The use of 123I-MIBG
(the best reported imaging modality for cardiac sympathetic
denervation) is highly reproducible and is an easily accessi-
ble method, making it not readily substituted by other mo-
dalities. Furthermore, lower HMR and higher wash-out rates
correspond to severity of the disease.
The use of 123I-MIBG has been studied most intensively
in patients with FAP. The 123I-MIBG results in this study
were generally less aberrant than those in previous studies
[4–6, 8]. Not only did the healthy controls have higher
HMR than in previous studies, but our amyloidosis patients
also showed higher 123I-MIBG uptake and less wash-out. In
the study of patients with FAP who underwent liver
transplantation, the mean HMR was 1.45±0.29 before and
1.46±0.28 after liver transplantation. Also the wash-out rate
in these patients (28.5±9.1 % and 24.6±9.6 %, respectively)
was higher than in our group. The most important explana-
tion of the large difference lies in the collimator type used.
The previous studies all used low-energy collimators,
whereas in this study a medium-energy collimator was used.
The choice of collimator type influences the HMR, with
higher HMR on 123I-MIBG scintigraphy with a medium-
energy collimator than with a low-energy collimator for
scans performed in the same setting [13]. Another explana-
tion may be the use of different 123I-MIBG specific activi-
ties in Japan, the US and The Netherlands. In this study the
specific activity of 123I-MIBG was 74 MBq/ml (Adreviwew,
GE Healthcare). Unfortunately, the specific activity of 123I-
MIBG used in previous studies is not available.
The use of 123I-MIBG in AL type amyloidosis has been
less intensively studied. Only one major study has been
performed in which the presence of impaired myocardial
sympathetic innervation was found to be related to clinical
autonomic abnormalities and congestive heart failure in AL
amyloidosis [9]. The mean late HMR in our group of AL
patients was higher than the mean value in the control group
in the previous study in patients before liver transplantation
[6]. The wash-out rate in the control group in the previous
study was generally over 20 %, whereas in our patients the
median wash-out rate was 8 %. This may indicate either that
different ethnic groups have different 123I-MIBG kinetics or
that patients with early stage amyloidosis, as in our patients,
have a less-intense wash-out of 123I-MIBG than patients
with later stage amyloidosis.
In our patients, no relationship was found between 123I-
MIBG uptake and autonomic dysfunction on bedside
manoeuvres, or peripheral neuropathy. In other groups with
both FAP and AL type amyloidosis, patients with either
autonomic or peripheral neuropathy had lower late HMR
and higher wash-out rates. This may also be due to the early
stage of the amyloidosis in our patients. This may imply a
differential autonomic neuropathy, which means that cardiac
autonomic dysfunction cannot be ruled out in those with
normal peripheral autonomic function. Despite the fact that
ten of our AL patients suffered from polyneuropathy and 18
suffered from autonomic neuropathy, we were not able to
identify a correlation between the presence of neuropathy
and low HMR or high wash-out rate. This may have been
due to the lower test characteristics of the autonomic func-
tion tests. Furthermore, no significant difference in HMR or
wash-out rate between the AL and AA patients was found.
This can be explained partly by the fact that fewer AA
patients show cardiac involvement. Another explanation
may be the fact that ATTR patients suffer from more severe
cardiac manifestations in the early stage of the disease. This
is in contrast to the general opinion that amyloidotic
Eur J Nucl Med Mol Imaging (2012) 39:1609–1617 1615
cardiomyopathy in ATTR patients is less aggressive than in
AL patients [14]. However, the prognosis in ATTR patients
depends on the type of mutation, age of onset and severity
of cardiac manifestations [15]. Since the age of the patients
in the different groups was not significantly different, the
explanation may be found in the severity of cardiac disease
and the type of mutation.
In our study, SPECT imaging was not performed routine-
ly. SPECT imaging has been reported to have advantages for
evaluating abnormalities in regional distribution in the myo-
cardium [4–9]. Usually, the reconstructed data are displayed
in three planes (short axis, horizontal long axis and vertical
long axis), which is similar to that used in myocardial
perfusion SPECT. Various patterns of distribution of myo-
cardial 123I-MIBG accumulation have been reported, but the
quality of 123I-MIBG SPECT images is moderate due to the
properties of the tracer. Furthermore, no myocardial perfu-
sion scans were performed. Comparing perfusion imaging to
123I-MIBG distribution gives extra information about the
presence or absence of mismatch patterns. Myocardial is-
chaemia or infarction disrupts sympathetic transmission,
which may lead to denervation of a region larger than that
affected by ischaemia only. Furthermore, sympathetic ner-
vous tissue is more sensitive to ischaemia than myocytes.
The presence of innervation/perfusion imaging mismatches
correlates with electrophysiological abnormalities and in-
creasing inducibility of potential lethal arrhythmias [16, 17].
PET in cardiac denervation
Various PETanalogues of NE are also under investigation [18].
These are even more similar to NE than 123I-MIBG and show
advantages for imaging. 11C-meta-hydroxy-ephedrine (11C-
mHED) is the most commonly used PET tracer. It has a higher
sensitivity for the uptake-1 mechanism than 123I-MIBG, and is
not linked to the uptake-2 mechanism, which might allow
better differentiation between innervated and denervated myo-
cardium. In a group of 21 patients with LV dysfunction who
underwent both 123I-MIBG and 11C-mHED imaging, the cor-
relation between MIBG wash-out rate and mHED wash-out
rate was poor (r00.57), but the defect sizes on both early (r0
0.94) and late images (r00.88) with these two modalities were
more closely associated. Therefore, 11C-mHED seems to have
advantages over 123I-MIBG in the detection of regional abnor-
malities [19]. Other 11C-labelled tracers, including 11C-phene-
thylguanidine, are currently under investigation. Promising
results from a study in rats show that 11C-phenethylguanidine
and its analogues are transported more slowly that MIBG and
mHED, and therefore might provide more accurate measure-
ment of cardiac nerve density [20].
To the best of our knowledge no PET tracers have been
used to visualize cardiac denervation in patients with cardiac
manifestations of amyloidosis.
Clinical implications
The results and measurements in echocardiography depend on
the level of experience of the user and this may lead to inter-
observer variability. Experienced users may be able to detect
cardiac amyloidosis accurately and therefore at an early stage
of the disease. The fact that in patients with echocardiographic
parameters for amyloidosis, late 123I-MIBG uptake was lower
and wash-out rate was higher shows that the two investigations
may complement each other. Amyloidosis with cardiac in-
volvement is a difficult diagnosis and one imaging technique
may confirm the diagnosis or add value to the other. Both types
of investigations are well established in the work-up in patients
with amyloidosis and should be performed routinely.
Another point of interest is the role of 123I-MIBG in predict-
ing sudden cardiac death in patients with heart failure and even
the predictive value of appropriate implantable cardioverter-
defibrillator (ICD) therapy. Several studies indicate that lower
HMR is associated with an increased likelihood of an ICD
discharge [21, 22]. 123I-MIBG scanning may also be able to
play a role in decision making concerning ICD therapy in
patients with heart failure due to cardiac amyloidosis.
Conclusion
Patients with biopsy-proven amyloidosis and echocardio-
graphic findings of cardiac manifestations showed sig-
nificantly lower HMR and higher wash-out rate than
patients without these findings. Furthermore, 123I-MIBG
scintigraphy was able to detect cardiac sympathetic de-
nervation in ATTR patients before echocardiographic
evidence was apparent. 123I-MIBG scanning may suc-
cessfully detect cardiac sympathetic denervation in all
patients with early stage amyloidosis. Finally, 123I-
MIBG and echocardiography may complement each oth-
er in the diagnosis of cardiac manifestations of amy-
loidosis, and should be performed consecutively in a
routine manner.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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